Opis działalności
Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases. Moderna’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing the Company the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune and inflammatory diseases, independently and with strategic collaborators.
Zarząd & Rada nadzorcza
CEO |
Stéphane Bancel |
Zarząd |
Jamey Mock, Juan Andres, Kate Cronin, Shannon Thyme Klinger, Stephen Hoge, M.D., Tracey Franklin, Dr. Jerh Collins, Arpa Garay, Brad Miller |
Rada nadzorcza |
Dr. Noubar Afeyan, Elizabeth Nabel, M.D., Elizabeth Tallett, François Nader, M.D., Henri A. Termeer, Paul Sagan, Sandra Horning, M.D., Stéphane Bancel, David Rubenstein |
Dane firmy
Nazwa: |
Moderna Inc. |
Adres: |
200 Technology Square,Cambridge, Massachusetts 02139, USA |
Telefon: |
+1-617-714-6500 |
Fax: |
+1-617-583-1998 |
E-mail: |
info@modernatx.com
|
Internet: |
https://www.modernatx.com/ |
Przemysł: |
Biotechnologia |
Sektor: |
Biotechnologia |
Podsektor: |
Biotechnologia |
Koniec roku finansowego: |
31.12 |
Free float: |
- |
Data IPO: |
07.12.2018 |